Sun Pharmaceutical Industries Ltd, India’s largest drugmaker, has announced the appointment of Kirti Ganorkar as its new Managing Director, effective September 1, 2025, subject to shareholder approval at the upcoming Annual General Meeting. The appointment marks a significant leadership transition as Dilip Shanghvi steps aside from day-to-day operations to take on the role of Executive Chairman.
A Well-Planned Succession for Sustainable Growth
The leadership shift is the outcome of a structured succession plan, reflecting Sun Pharma’s commitment to long-term governance and business continuity. Ganorkar, who has been with the company since 1996, currently heads its India Business, where he has led consistent market share gains and strategic advancements.
With deep experience across business development, marketing, IP, M&A, and global expansion, Ganorkar has played a pivotal role in Sun’s transformation—steering major initiatives including entry into Japan and Europe, supporting U.S. generics, and launching innovative products such as Ilumya in the specialty space.
Leadership Realignment in North America
In a parallel announcement, Abhay Gandhi, President & CEO for North America, will step down to pursue opportunities outside the company. He will be succeeded by Rick Ascroft, a seasoned executive from Takeda Pharmaceuticals, who brings over 30 years of experience in commercial operations, market access, and medical affairs across the U.S. and global markets.
Aalok Shanghvi, Chief Operating Officer and Whole-Time Director, will take on expanded responsibilities to oversee the North America business, with Ascroft reporting directly to him.
Focus Areas Ahead
As Executive Chairman, Dilip Shanghvi will continue to lead the Board and focus on strengthening Sun Pharma’s specialty product portfolio while guiding its long-term strategic direction. His statement reinforced confidence in Ganorkar’s leadership and highlighted the company’s internal talent pipeline as a foundation for future growth.
The leadership changes signal Sun Pharma’s readiness to enter a new phase, leveraging global opportunities while reinforcing its market-leading presence in India. With Ganorkar at the helm and a refreshed executive team, the company is poised to accelerate innovation and expand its footprint in key therapeutic areas worldwide.